Table 1.
Chimerism of SCT
| SCT | HSCs, ×103 | Chimeras with donor engraftment*, % | Cell phenotype, %
|
|
|---|---|---|---|---|
| Donor origin | Recipient origin | |||
| B6 → BALB (fully allogeneic) | 100 | 5/6 (83) | 52.7 ± 10.8* | 48.0 ± 12.7 |
| 50 | 2/6 (33) | 33.8 ± 14.6* | 64.0 ± 11.4 | |
| 10 | 0/9 (0) | 2.3 ± 0.8 | 98.3 ± 2.2 | |
| B6 Ly-5.1 → (B6 × C3H) F1 (hemiallogeneic) | 10 | 7/7 (100) | 78.1 ± 7.9 | 24.1 ± 5.5 |
| 1 | 8/8 (100) | 52.2 ± 24.1* | 45.1 ± 24.9 | |
| 0.1 | 1/8 (13) | 6.0 ± 4.7 | 84.7 ± 3.6 | |
| B6 Ly-5.1 → B6 Ly-5.2 (congeneic) | 1 | 10/10 (100) | 89.2 ± 3.4 | 11.6 ± 1.6 |
| 0.1 | 12/12 (100) | 26.7 ± 5.6 | 64.9 ± 8.7 | |
| 0.01 | 1/12 (8) | 5.5 ± 4.3 | 93.1 ± 4.9 | |
Spleen cells of chimeras 4 months post-SCT were stained with FITC-conjugated anti-H-2 Kb or anti-Ly-5.1 for donor origin or with FITC-conjugated anti-H-2 Kd or anti-Ly-5.2 for recipient origin. Each group consisted of at least three recipients, and each experiment had been repeated at least once. Results are mean ± SD.
*
Only those chimeras with >10% of cells of donor origin were included in calculations of donor engraftment and those of mean ± SD.